Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Aquestive Therapeutics

Aquestive Therapeutics (NASDAQ: AQST) insider transactions

In the twelve months to 10 November 2026, executives and directors of Aquestive Therapeutics reported 16 open-market sales of 562,697 shares ($2.4m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Aquestive Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
21 October 2026Cochran JohnDirectorOther+62,229—161,715Form 4
15 October 2026Barber DanielPresident and CEOOpen-market sale, 10b5-1 plan−25,000$4.22627,317Form 4
15 September 2026Barber DanielPresident and CEOOpen-market sale, 10b5-1 plan−25,000$4.82652,317Form 4
9 September 2026Korczynski SherryChief Commercial OfficerOption exercise, 10b5-1 plan+8,750$2.65244,439Form 4
9 September 2026Korczynski SherryChief Commercial OfficerOpen-market sale, 10b5-1 plan−8,750$5.22235,689Form 4
9 September 2026Boyd Peter E.Chief People OfficerOption exercise+2,293$0.96284,024Form 4
8 September 2026Barber DanielPresident and CEOOption exercise+91,743$0.96677,317Form 4
3 September 2026Jung CassieChief Operating OfficerOption exercise+4,587$0.96206,833Form 4
17 August 2026Barber DanielPresident and CEOOpen-market sale, 10b5-1 plan−25,000$4.29585,574Form 4
14 August 2026Korczynski SherryChief Commercial OfficerShares withheld for tax−2,714$4.25235,689Form 4
16 July 2026Barber DanielPresident and CEOOpen-market sale, 10b5-1 plan−20,369$4.00610,574Form 4
15 July 2026Barber DanielPresident and CEOOpen-market sale, 10b5-1 plan−4,631$4.03630,943Form 4
23 June 2026Krop JulieDirectorOption exercise, 10b5-1 plan+25,000$0.7125,000Form 4
23 June 2026Krop JulieDirectorOpen-market sale, 10b5-1 plan−25,000$5.020Form 4
15 June 2026Barber DanielPresident and CEOOpen-market sale, 10b5-1 plan−25,000$4.16635,574Form 4
8 June 2026Korczynski SherryChief Commercial OfficerShares withheld for tax−2,714—238,403Form 4
18 May 2026Zalewski Thomas A.Chief Legal OfficerGrant or award+100,000—100,000Form 4
15 May 2026Cioffi MelinaSVP, Regulatory AffairsShares withheld for tax−1,667$4.17273,200Form 4
15 May 2026Barber DanielPresident and CEOOpen-market sale, 10b5-1 plan−8,257$4.29660,574Form 4
7 May 2026Braender Lori JCorporate SecretaryShares withheld for tax−135,690$4.23231,042Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Aquestive Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.